Aprecia, the pharmaceutical company who has licensed rights to pharmaceutical applications for 3-D Printing (3DP), has developed a ground-breaking drug for the treatment of certain seizures in those suffering from epilepsy.
The drug in question – called Spritam – is the first medication approved by the FDA utilizing this 3DP platform with the first batch of pills expected to hit the shelf by early next year.
“By combining 3DP technology with a highly-prescribed epilepsy treatment, Spritam is designed to fill a need for patients who struggle with their current medication experience,” said Don Wetherhold, who is the CEO of Aprecia, the pharmaceutical company behind the drug.
“This is the first in a line of central nervous system products Aprecia plans to introduce as part of our commitment to transform the way patients experience taking medication.” There are actually a number of advantages to 3D printing drugs. By layering the medication, they can pack in more of the active ingredient into a smaller pill, delivering up to 1,000 milligrams in a single, easily taken dose. Read more about Aprecia’s story [here] .